Vitamin-D deficiency impairs CD4+T-cell count recovery rate in HIV-positive adults on highly active antiretroviral therapy: A longitudinal study.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

According to the abstract, 398 adults were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The researchers used data from a randomized placebo-controlled micronutrient trial with 25-hydroxy vitamin-D (25(OH)D) measured at enrollment in 398 adults.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The adults were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

CD4+T-cell count was measured repeatedly at months 0, 3, 6, 12 and 18.

What Was Measured

The subject headings attached to it are Antiretroviral Therapy, Highly Active, Body Mass Index, CD4 Lymphocyte Count, Dietary Supplements, HIV Infections, Longitudinal Studies and Socioeconomic Factors.

Author keywords: CD4+, Immune recovery, T-cell count and Vitamin-D.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 398 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.